Zaheer Aslam, MD
Addiction Psychiatry · Fort Myers, FLNPI 1609950468
Payments from drug & device makers
What this record shows
Merck accounts for 76.6% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $1,086 and has fallen 96.7% since, to $36 in 2025.
Across 24 payments — averaging $56.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1K
- Alkermes, Inc.$84
- Johnson & Johnson$51
- Braeburn Inc.$38
- Almatica Pharma LLC$31
- Otsuka America Pharmaceutical, Inc.$24
- plus $88 from 5 others
Across 365 payments — averaging $5594.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$468K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$372K
- Supernus Pharmaceuticals, Inc.$273K
- Boehringer Ingelheim$198K
- Arbor Pharmaceuticals, Inc.$171K
- AbbVie$162K
- plus $398K from 10 others
What the payments were for
- Travel & lodging$77958%
- Food & beverage$57442%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 8 | $1,036 |
| Alkermes, Inc. | 4 | $84 |
| Johnson & Johnson | 2 | $51 |
| Braeburn Inc. | 2 | $38 |
| Almatica Pharma LLC | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Eisai Inc. | 1 | $22 |
| AbbVie | 1 | $18 |
| Indivior Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Neurocrine Biosciences, Inc. | 1 | $13 |
How this compares
$1,352 in reported general payments places this provider in the 65th percentile of 29 addiction psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 11 | $62,639 |
| SpravatoEsketamine Hcl | 25 | $35,230 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 154 | $22,607 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 27 | $22,370 |
| Seroquel XrQuetiapine Fumarate | 13 | $18,733 |
| RexultiBrexpiprazole | 12 | $18,655 |
| VraylarCariprazine Hcl | 12 | $17,292 |
| AuvelityDextromethorphan Hbr/Bupropion | 16 | $15,896 |
| Aripiprazole | 134 | $6,924 |
| VyvanseLisdexamfetamine Dimesylate | 19 | $6,797 |
| Quetiapine Fumarate | 160 | $2,818 |
| Bupropion XlBupropion Hcl | 174 | $2,750 |
| SeroquelQuetiapine Fumarate | 12 | $2,310 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 41 | $2,023 |
| Ziprasidone Hcl | 31 | $1,759 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $51 | $35,23025 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $24 | $18,65512 claims |
| AbbVieVraylar | $18 | $17,29212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 29 addiction psychiatry providers in Florida.
Other addiction psychiatry in Fort Myers
- Raul RodriguezDelray Beach$31K
- Jason FieldsNew Port Richey$26K
- Edward BariasJupiter$21K
- Mary SheehanTampa$16K
- Aldo MoralesFort Lauderdale$13K
- Krishan BatraOdessa$10K
- Lawrence WeinsteinSt Petersburg$6K
- Syed ZaidiPinellas Park$5K
- Vincence DillonPensacola$2K
- Curtis PhillipsDelray Beach$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.